AUGUSTINE THERAPEUTICS
0722.705.230 · rovalta.com · 05/11/2026
ACTIVE
AUGUSTINE THERAPEUTICS
Financial year 2025 · Closed on 31/12/2025
Net result-14,8 M €-72,7 %over 1 year
Gross margin-1,7 M €+5,0 %over 1 year
Equity29 M €+328,2 %over 1 year
Workforce11,0 ETP+103,7 %over 1 year
Overview
Identity
Source · BCE/KBOAUGUSTINE THERAPEUTICS is a Public limited company incorporated in 2019. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Leuven. It employs on average 11,0 ETP workers (FTE).
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0722.705.230
- Incorporation
- 13/03/2019
- Legal form
- Public limited company
- Registered office
- Gaston Geenslaan 3
3001 Leuven · FlandreSee on map - Contributed capital
- 52 329 665,17 €
- Latest accounts
- 31/12/2025
- Average workforce
- 11,0 ETP
Activities (NACE)
Joint committees (1)
- 207
Signals
Solid equityLow riskGood liquidity
Financials
Source · NBB, 6 filingsTrend over 5 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | -1,7 M € | +5.0% | -1,7 M € | -238% | -515,8 k € | +74.0% | -2 M € | -35.4% | -1,5 M € |
| EBITDA | -3,2 M € | -25.8% | -2,6 M € | -175% | -930,1 k € | +58.3% | -2,2 M € | -48.8% | -1,5 M € |
| Operating result | -15,7 M € | -82.2% | -8,6 M € | -112% | -4,1 M € | -35.2% | -3 M € | -72.6% | -1,7 M € |
| Net result | -14,8 M € | -72.7% | -8,6 M € | -106% | -4,2 M € | -33.0% | -3,1 M € | -75.8% | -1,8 M € |
| Balance sheet | |||||||||
| Equity | 29 M € | +328% | 6,8 M € | +409% | -2,2 M € | -211% | 2 M € | +265% | 541 k € |
| Total assets | 30,9 M € | +250% | 8,8 M € | +66.2% | 5,3 M € | +96.1% | 2,7 M € | -39.4% | 4,5 M € |
| Cash | 656,4 k € | -91.5% | 7,8 M € | +104% | 3,8 M € | +141% | 1,6 M € | -39.4% | 2,6 M € |
| Debts | 1,9 M € | -3.8% | 2 M € | -72.0% | 7,2 M € | +1044% | 625,9 k € | -81.6% | 3,4 M € |
| Other | |||||||||
| Workforce | 11,0 ETP | +104% | 5,4 ETP | – | – | 0,7 ETP | |||
Valuation
Indicative valuation
As an indication, this company is worth
between 25 M€ and 50 M€
See the valuationBoard of directors
Source · NBB, accounts to 31/12/20259 active · 5 ended
Active mandates
| Director | Mandates in this company | Period | Other mandatescurrentendedstruck offbankruptcies |
|---|---|---|---|
Pascale Florence Geneviève Witz | Director01/03/2025 → 14/05/2031 | ||
Clara Campàs Moya | Director31/01/2025 → 14/05/2031 | ||
Emmanuelle Coutanceau | Director31/01/2025 → 14/05/2031 | ||
Gerhard Koenig | Director28/03/2022 → 14/05/2031 | ||
Mahieddine El Mahdi Ainouche | Director31/01/2025 → 14/05/2031 | ||
| Director10/12/2020 → 14/05/2031 | |||
Alain Huriez | Director26/11/2019 → 14/05/2025 | ||
Sylvain Celanire | Managing director01/04/2020 → 14/05/2025 | ||
Ward Capoen | Director12/03/2019 → 14/05/2025 |
Ended mandates
| Director | Mandates in this company | Period | Other mandatescurrentendedstruck offbankruptcies |
|---|---|---|---|
Eureka Consulting LLC | Directorlisted until the 2023 accounts | ||
Erik Tambuyzer | Director01/04/2020 → 10/12/2020 | ||
Bart Geers | Director26/11/2019 → 2024 accounts |
Other companies at this address
Gaston Geenslaan 3 3001 Leuven| Company | CBE no. |
|---|---|
AstriVax Therapeutics● Active | 0787.990.881 |
COULTREON BIOPHARMA● Active | 1019.429.814 |
K5 Therapeutics● Active | 0757.718.072 |
Metaptys● Active | 0554.664.311 |
Montis Biosciences● Active | 0730.979.429 |
Perseus Biomics● Active | 0650.946.412 |
QUOMAK● Active | 0448.488.111 |
ReWind Therapeutics● Active | 0682.626.216 |
| 1040.853.946 | |
Tavira Therapeutics● Active | 0802.591.262 |
VEDRA THERAPEUTICS● Active | 1039.565.628 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Micro model | Micro model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/03/2019 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 22 months |
| Filing date | 05/06/2026 | 21/05/2025 | 27/06/2024 | 29/06/2023 | 07/06/2022 | 31/05/2021 |
| General meeting | 13/05/2026 | 14/05/2025 | 13/06/2024 | 10/05/2023 | 11/05/2022 | 27/05/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 6 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 13/05/2026 | 05/06/2026 | Dutch | |
| Abridged model | 31/12/2024 | 14/05/2025 | 21/05/2025 | Dutch | |
| Micro model | 31/12/2023 | 13/06/2024 | 27/06/2024 | Dutch | |
| Micro model | 31/12/2022 | 10/05/2023 | 29/06/2023 | Dutch | |
| Abridged model | 31/12/2021 | 11/05/2022 | 07/06/2022 | Dutch | |
| Abridged model | 31/12/2020 | 27/05/2021 | 31/05/2021 | Dutch |
Valuation
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 25 M€ and 50 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20259 active · 5 ended
Active mandates
| Director | Mandates in this company | Period | Other mandatescurrentendedstruck offbankruptcies |
|---|---|---|---|
Pascale Florence Geneviève Witz | Director01/03/2025 → 14/05/2031 | ||
Clara Campàs Moya | Director31/01/2025 → 14/05/2031 | ||
Emmanuelle Coutanceau | Director31/01/2025 → 14/05/2031 | ||
Gerhard Koenig | Director28/03/2022 → 14/05/2031 | ||
Mahieddine El Mahdi Ainouche | Director31/01/2025 → 14/05/2031 | ||
| Director10/12/2020 → 14/05/2031 | |||
Alain Huriez | Director26/11/2019 → 14/05/2025 | ||
Sylvain Celanire | Managing director01/04/2020 → 14/05/2025 | ||
Ward Capoen | Director12/03/2019 → 14/05/2025 |
Ended mandates
| Director | Mandates in this company | Period | Other mandatescurrentendedstruck offbankruptcies |
|---|---|---|---|
Eureka Consulting LLC | Directorlisted until the 2023 accounts | ||
Erik Tambuyzer | Director01/04/2020 → 10/12/2020 | ||
Bart Geers | Director26/11/2019 → 2024 accounts |
Ownership and network
Looking for more information about this company?
Try for freePublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Mandates17/06/2025DIVERSEN - ONTSLAGEN - BENOEMINGEN
- Mandates21/05/2025ONTSLAGEN - BENOEMINGEN
- Mandates12/02/2025STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
- Mandates01/07/2024STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
- Mandates29/11/2023ONTSLAGEN - BENOEMINGEN
- Mandates20/10/2023ONTSLAGEN - BENOEMINGEN
- Registered office20/09/2023MAATSCHAPPELIJKE ZETEL
- Capital / shares03/01/2023KAPITAAL - AANDELEN
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
Source · CBE, NBB annual accountsYear
Identity
Incorporation
Name
Registered office
Annual accounts
Filings5 filings
Mandates
Pascale Florence Geneviève Witz
Participatiemaatschappij Vlaanderen
Clara Campàs Moya
Mahieddine El Mahdi Ainouche
Emmanuelle Coutanceau
Gerhard Koenig
Ward Capoen
Sylvain Celanire
Alain Huriez
Eureka Consulting LLC
Erik Tambuyzer
Bart Geers
2019202020212022202320242025202620272028202920302031
AUGUSTINE THERAPEUTICS
Gaston Geenslaan 3, 3001 HeverleeGaston Geenslaan 1, 3001 Heverlee
Director
Director
Director
Director
Director
Director
Director
Managing director
Director
Director
CurrentPlanned, not yet servedEndedAccounts filedToday
Registered offices
Source · NBB annual accounts, CBE| Registered address | Period | Source |
|---|---|---|
| Gaston Geenslaan 3, 3001 HeverleeCurrent | accounts 2023 → 2025 | Accounts 2025 · 2026-00146394 |
| Gaston Geenslaan 1, 3001 Heverlee | accounts 2021 → 2022 | Accounts 2022 · 2023-00203561 |
Company names
Source · NBB annual accounts, CBE| Name | Period | Source |
|---|---|---|
| AUGUSTINE THERAPEUTICSCurrent | accounts 2021 → 2025 | Accounts 2025 · 2026-00146394 |
Events
- 2025Annual accounts 2025-14,8 M €↓
- 2024Annual accounts 2024-8,6 M €↓
- 2023Annual accounts 2023-4,2 M €↓
- 2022Annual accounts 2022-3,1 M €↓
- 2021Annual accounts 2021-1,8 M €
- 13/03/2019IncorporationPublic limited company